Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefepime Hydrochloride

FDA-approved product (injectable, injection), marketed as Cefepime And Dextrose In Duplex Container, Cefepime Hydrochloride, Cefepime Hydrochloride In Plastic Container and 2 more.

Registered studies
50+
Lab records
203
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefepime Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacteriemia
  • Infection
  • Pneumonia
  • Pyelonephritis
  • Sprain
  • Urinary tract infection
  • Ventilator-associated pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fourth-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DE01

Repurposing investigation

Cefepime Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis50.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 95 of 203 lab records
Open Cefepime Hydrochloride in ChEMBL Registered studies below
Show the latest 150 of 203 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefepime Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI

    NCT03680612 · start 2017-09-05

    Registered record
    Registry ID
    NCT03680612
    Conditions
    Urinary Tract Infections
    Interventions
    Cefepime 1G - 2G / AAI101 0.5G - 0.75G; cefepime 1 g or cefepime 2 g
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-09-05
    Completion
    2018-02-14
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionCefepime 1G - 2G / AAI101 0.5G - 0.75G; cefepime 1 g or cefepime 2 g
    PhasePhase 2
    Registry statusCompleted

  • Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)

    NCT03680378 · start 2017-07-01

    Registered record
    Registry ID
    NCT03680378
    Conditions
    Healthy Subjects
    Interventions
    Cefepime 2 gram
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-07-01
    Completion
    2019-04-30
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionCefepime 2 gram
    PhasePhase 1
    Registry statusCompleted

  • Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

    NCT03078010 · start 2017-02-10

    Registered record
    Registry ID
    NCT03078010
    Conditions
    Intestinal Microbiome; Febrile Neutropenia
    Interventions
    Piperacillin-tazobactam; cefepime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2017-02-10
    Completion
    2027-02
    Enrolment
    347

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Microbiome; Febrile Neutropenia
    InterventionPiperacillin-tazobactam; cefepime
    PhasePhase 2
    Registry statusActive not recruiting

  • Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae

    NCT02795949 · start 2016-10

    Registered record
    Registry ID
    NCT02795949
    Conditions
    Enterobacteriaceae Infections
    Interventions
    Antipseudomonal beta-lactam antibiotic; De-escalation(short-spectrum antibiotic)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-10
    Completion
    2020-01
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnterobacteriaceae Infections
    InterventionAntipseudomonal beta-lactam antibiotic; De-escalation(short-spectrum antibiotic)
    PhasePhase 3
    Registry statusCompleted

  • A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

    NCT02709382 · start 2016-03

    Registered record
    Registry ID
    NCT02709382
    Conditions
    Renal Impairment
    Interventions
    Cefepime and Tazobactam combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-08
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment
    InterventionCefepime and Tazobactam combination
    PhasePhase 1
    Registry statusCompleted

  • An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections

    NCT02302092 · start 2015-12-01

    Registered record
    Registry ID
    NCT02302092
    Conditions
    Urinary Tract Infection
    Interventions
    Flomoxef; Cefepime
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-12-01
    Completion
    2016-12-15
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection
    InterventionFlomoxef; Cefepime
    PhasePhase 3
    Registry statusTerminated

  • Prolonged Infusion Cefepime and Nosocomial Infections

    NCT02568800 · start 2015-10

    Registered record
    Registry ID
    NCT02568800
    Conditions
    Urinary Tract Infection; Respiratory Tract Infection
    Interventions
    Prolonged Cefepime Infusion; Usual Cefepime Infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-10
    Completion
    2016-09
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection; Respiratory Tract Infection
    InterventionProlonged Cefepime Infusion; Usual Cefepime Infusion
    PhasePhase 3
    Registry statusUnknown

  • Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)

    NCT02497781 · start 2015-09-24

    Registered record
    Registry ID
    NCT02497781
    Conditions
    Complicated Urinary Tract Infections
    Interventions
    Ceftazidime -avibactam; Cefepime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-09-24
    Completion
    2017-09-15
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infections
    InterventionCeftazidime -avibactam; Cefepime
    PhasePhase 2
    Registry statusCompleted

  • Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

    NCT02872038 · start 2015-08

    Registered record
    Registry ID
    NCT02872038
    Conditions
    Peritoneal Dialysis Associated Peritonitis
    Interventions
    Cefepime; Cefazolin plus Ceftazidime
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-08
    Completion
    2016-11-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeritoneal Dialysis Associated Peritonitis
    InterventionCefepime; Cefazolin plus Ceftazidime
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

    NCT01431326 · start 2011-11

    Registered record
    Registry ID
    NCT01431326
    Conditions
    Adenovirus; Anesthesia; Anxiety; Anxiolysis; Autism; Autistic Disorder; Bacterial Meningitis; Bacterial Septicemia; Benzodiazepine; Bipolar Disorder; Bone and Joint Infections; Central Nervous System Infections; Convulsions; Cytomegalovirus Retinitis; Early-onset Schizophrenia Spectrum Disorders; Epilepsy; General Anesthesia; Gynecologic Infections; Herpes Simplex Virus; Infantile Hemangioma; Infection; Inflammation; Inflammatory Conditions; Intra-abdominal Infections; Lower Respiratory Tract Infections; Migraines; Pain; Pneumonia; Schizophrenia; Sedation; Seizures; Skeletal Muscle Spasms; Skin and Skin-structure Infections; Treatment-resistant Schizophrenia; Urinary Tract Infections; Withdrawal; Sepsis; Gram-negative Infection; Bradycardia; Cardiac Arrest; Cardiac Arrhythmia; Staphylococcal Infections; Nosocomial Pneumonia; Neuromuscular Blockade; Methicillin Resistant Staphylococcus Aureus; Endocarditis; Neutropenia; Headache; Fibrinolytic Bleeding; Pulmonary Arterial Hypertension; C
    Interventions
    The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-11
    Completion
    2019-11
    Enrolment
    3,520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenovirus; Anesthesia; Anxiety; Anxiolysis +47 more
    InterventionThe POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusCompleted

  • Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

    NCT01484015 · start 2011-02

    Registered record
    Registry ID
    NCT01484015
    Conditions
    Adult Acute Lymphoblastic Leukemia; Adult Acute Myeloid Leukemia; Adult Burkitt Lymphoma; Adult Diffuse Large Cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Hodgkin Lymphoma; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Breast Cancer; Chronic Eosinophilic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Cutaneous T-cell Non-Hodgkin Lymphoma; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Malignant Testicular Germ Cell Tumor; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Multiple Myeloma; Mycosis Fungoides/Sezary Syndrome; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neutropenia; Nodal Marginal Zone B-
    Interventions
    cefepime hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    2012-10
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Acute Lymphoblastic Leukemia; Adult Acute Myeloid Leukemia; Adult Burkitt Lymphoma; Adult Diffuse Large Cell Lymphoma +27 more
    Interventioncefepime hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

    NCT01110421 · start 2010-12

    Registered record
    Registry ID
    NCT01110421
    Conditions
    Pneumonia, Bacterial; Community-Acquired Infections; Nosocomial Infection; Pneumonia, Ventilator-Associated
    Interventions
    Cefepime placebo; Cefepime; Doripenem; Doripenem placebo; Amoxicillin/clavulanate potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-12
    Completion
    2012-03
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia, Bacterial; Community-Acquired Infections; Nosocomial Infection; Pneumonia, Ventilator-Associated
    InterventionCefepime placebo; Cefepime; Doripenem; Doripenem placebo +1 more
    PhasePhase 3
    Registry statusTerminated

  • A Study of Ceftobiprole in Patients With Fever and Neutropenia.

    NCT00529282 · start 2007-10

    Registered record
    Registry ID
    NCT00529282
    Conditions
    Fever; Neutropenia; Gram-positive Bacterial Infections; Pseudomonas Infection
    Interventions
    Ceftobiprole Medocaril; Cefepime with or without vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2007-10
    Completion
    2008-01
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFever; Neutropenia; Gram-positive Bacterial Infections; Pseudomonas Infection
    InterventionCeftobiprole Medocaril; Cefepime with or without vancomycin
    PhasePhase 3
    Registry statusTerminated

  • Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion

    NCT00435305 · start 2006-11

    Registered record
    Registry ID
    NCT00435305
    Conditions
    Pneumonia; Bacteremia
    Interventions
    Meropenem; Vancomycin; Linezolid; Piperacillin/Tazobactam; Cefepim; Ceftazidim
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2006-11
    Completion
    2007-11
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Bacteremia
    InterventionMeropenem; Vancomycin; Linezolid; Piperacillin/Tazobactam +2 more
    PhaseNot recorded
    Registry statusTerminated

  • Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen

    NCT00609375 · start 2006-09

    Registered record
    Registry ID
    NCT00609375
    Conditions
    Sepsis; Bacteremia
    Interventions
    cefepime; cefepime
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-09
    Completion
    2007-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Bacteremia
    Interventioncefepime; cefepime
    PhasePhase 4
    Registry statusCompleted